SUDA Pharmaceuticals Ltd (ASX:SUD) is encouraged by preliminary results received from a pharmacokinetic study evaluating novel mouth spray formulations of anagrelide.
The study, which involved comparing three different mouth spray formulations against the current commercial capsule in a canine model, has been conducted by leading contract research organisation, Covance Inc, based in Harrogate, England.
Preliminary results from the crossover study using five animals suggest that one of the formulations was able to increase the bioavailability of anagrelide while reducing exposure to a cardio stimulatory metabolite.
This supports SUDA’s hypothesis that such a formulation could be more safely administered to cancer patients, potentially resulting in fewer cardiovascular side-effects.
Suda will update the market with the results when the report has been finalised.
Working with “world-class people and research organisations”
Chief executive officer Dr Michael Baker said: “This is an exciting time for SUDA as we continue to advance this important project.
“There is still work to be done but we are making progress by working with world-class people and world-leading contract research organisations.”
The company will continue optimising the formulation to meet the requirements for a pharmaceutical-grade oral spray product before completing further preclinical testing.
Shares are up almost 7% to 4.6 cents.
SUDA Pharmaceuticals, which is headquartered in Perth, is a drug delivery company focused on oro-mucosal administration and is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals.
The many potential benefits of administering drugs through the oral mucosa (ie cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time.